GlassScriptPhysician profile
Sarah L Cunningham
NPI 1962941641
$1,196.71
in general payments reported to CMS, 2019-2025
24 companies · $442 in 2025
The $442 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $56.03 · 2023: $406 · 2024: $292 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,140.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $294.81 | 2023-2025 | Vraylar, Viberzi, Linzess |
| Pfizer INC. | $139.29 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $135.36 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $82.66 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $76.14 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $71.31 | 2023-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.08 | 2023-2024 | Jardiance, Ofev |
| Abbott Laboratories | $31.00 | 2025 | Freestyle Libre 2 |
| Idorsia Pharmaceuticals US INC | $28.61 | 2022-2023 | Quviviq |
| Merck Sharp & Dohme LLC | $26.73 | 2023-2024 | Vaxelis, Gardasil 9, Vaxneuvance |
| Organon LLC | $25.91 | 2025 | Nexplanon |
| Vbi Vaccine (Delaware) INC. | $20.40 | 2023 | Prehevbrio |
| Corcept Therapeutics | $19.77 | 2023 | Korlym |
| Xeris Pharmaceuticals, INC. | $19.21 | 2023 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $18.64 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $18.61 | 2024 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $18.44 | 2024 | |
| Amgen INC. | $16.93 | 2025 | Repatha |
| Glaxosmithkline, LLC. | $16.36 | 2025 | Bexsero, Shingrix, Arexvy |
| Sanofi Pasteur INC. | $15.17 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $14.88 | 2023 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.86 | 2022 | |
| Dexcom, INC. | $12.77 | 2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $11.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.